Bright Minds Biosciences Inc banner
B

Bright Minds Biosciences Inc
CNSX:DRUG

Watchlist Manager
Bright Minds Biosciences Inc
CNSX:DRUG
Watchlist
Price: 109.06 CAD -2.2% Market Closed
Market Cap: CA$1.1B

Relative Value

There is not enough data to reliably calculate the relative value of DRUG.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DRUG Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

DRUG Competitors Multiples
Bright Minds Biosciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Bright Minds Biosciences Inc
CNSX:DRUG
1.1B CAD 0 -66.2 -69.2 -68.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 643 258.8 -159 901.4 -194 171.3 -191 955.6
US
Abbvie Inc
NYSE:ABBV
395.8B USD 6.6 168.6 16.3 23.2
US
Amgen Inc
NASDAQ:AMGN
202.7B USD 5.5 26.3 15 15
US
Gilead Sciences Inc
NASDAQ:GILD
188B USD 6.4 22.1 15 15
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD 9.9 30.1 23 24
US
Epizyme Inc
F:EPE
94.1B EUR 2 094 -534.3 -581.8 -566.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD 5.8 18.3 13.9 15.8
AU
CSL Ltd
ASX:CSL
74.1B AUD 3.3 17.2 11.8 14.7
NL
argenx SE
XBRU:ARGX
44.2B EUR 14.5 34 58.5 60.1
US
Seagen Inc
F:SGT
39.3B EUR 20.2 -61.8 -66.7 -60.2
P/S Multiple
Revenue Growth P/S to Growth
CA
B
Bright Minds Biosciences Inc
CNSX:DRUG
Average P/S: 3 364 542.5
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 643 258.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.5
2%
2.8
US
Gilead Sciences Inc
NASDAQ:GILD
6.4
5%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 094
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.8
9%
0.6
AU
CSL Ltd
ASX:CSL
3.3
5%
0.7
NL
argenx SE
XBRU:ARGX
14.5
49%
0.3
US
S
Seagen Inc
F:SGT
20.2
30%
0.7
P/E Multiple
Earnings Growth PEG
CA
B
Bright Minds Biosciences Inc
CNSX:DRUG
Average P/E: 45.2
Negative Multiple: -66.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 901.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
26.3
18%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
22.1
14%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.1
17%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.3
13%
1.4
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
NL
argenx SE
XBRU:ARGX
34
42%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
B
Bright Minds Biosciences Inc
CNSX:DRUG
Average EV/EBITDA: 21.9
Negative Multiple: -69.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 171.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
15
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
15
18%
0.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
15%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.9
23%
0.6
AU
CSL Ltd
ASX:CSL
11.8
8%
1.5
NL
argenx SE
XBRU:ARGX
58.5
810%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
B
Bright Minds Biosciences Inc
CNSX:DRUG
Average EV/EBIT: 24
Negative Multiple: -68.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -191 955.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
15
2%
7.5
US
Gilead Sciences Inc
NASDAQ:GILD
15
11%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.8
21%
0.8
AU
CSL Ltd
ASX:CSL
14.7
11%
1.3
NL
argenx SE
XBRU:ARGX
60.1
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.2 N/A N/A